AbbVie to Present at the Morgan Stanley Healthcare Conference
AbbVie will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on September 16, 2020, at 10 a.m. Central time. CEO Richard A. Gonzalez will present, and the session will be available via a live audio webcast on AbbVie's Investor Relations website, with an archived edition accessible later that day.
AbbVie aims to deliver innovative medicines across key therapeutic areas, including immunology, oncology, and neuroscience, and has a commitment to address serious health challenges.
- None.
- None.
NORTH CHICAGO, Ill., Sept. 3, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020. Richard A. Gonzalez, chairman and chief executive officer, will present at 10 a.m. Central time.
A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
View original content:http://www.prnewswire.com/news-releases/abbvie-to-present-at-the-morgan-stanley-healthcare-conference-301123472.html
SOURCE AbbVie
FAQ
When is AbbVie's presentation at the Morgan Stanley Healthcare Conference?
Who will present for AbbVie at the conference?
Where can I access the webcast of AbbVie's presentation?
Will there be a recording of the AbbVie presentation available?
What are AbbVie's focus therapeutic areas?
